Second PIC/S GMP Certification | Mabwell Passes Brazilian GMP Inspection for Its Denosumab Injections
· manilatimes.net
SHANGHAI, Aug. 10, 2026 /PRNewswire/ -- Mabwell (688062.SH, 02493.HK), an innovation-driven biopharmaceutical company with a fully integrated industry chain, announces that its wholly-owned subsidiary T-mab has successfully passed Brazilian Health Regulatory Agency's ('ANVISA') GMP on-site inspection for its denosumab biosimilars, 9MW0311 (Prolia® biosimilar) and 9MW0321 (Xgeva® biosimilar). This is Mabwell's second GMP certification from a Pharmaceutical Inspection Co-operation Scheme (PIC/S) member authority, following the one in Jordan.
SHANGHAI, Aug. 10, 2026 /PRNewswire/ -- Mabwell (688062.SH, 02493.HK), an innovation-driven biopharmaceutical company with a fully integrated industry chain, an...